Most Bought By Hedge Funds

10.92k followers • 30 symbols Watchlist by Yahoo Finance

Follow this list to discover and track the stocks that were bought the most by hedge funds in the last quarter.

30 Symbols

Get the Yahoo Finance app

Free real-time data
News and price alerts
Add and edit holdings
Track performance
Create multiple watchlists

Zacks
Synopsys (SNPS) to Post Q3 Earnings: What's in the Offing?
Synopsys' (SNPS) third-quarter fiscal 2019 results are likely to benefit from the increasing uptake of its strong product portfolio. However, Huawei ban remains a major headwind for the company.
Zacks
YUMC or SHAK: Which Is the Better Value Stock Right Now?
YUMC vs. SHAK: Which Stock Is the Better Value Option?
Zacks
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
Zacks
Dow, S&P Rebound as Consumers Calm Market
Dow, S&P; Rebound as Consumers Calm Market
Zacks
IQIYI, Inc. Sponsored ADR (IQ) Gains But Lags Market: What You Should Know
In the latest trading session, iQIYI, Inc. Sponsored ADR (IQ) closed at $16.97, marking a +0.24% move from the previous day.
Zacks
BJ's Wholesale Club (BJ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BJ's (BJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
FDA Resets PAD Guidelines: The Road Ahead for Device Makers
On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.
Zacks
Cardiovascular Systems Set to Present LIBERTY 360 Outcome
This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).
Zacks
Company News For Aug 15, 2019
Companies In The News Are: W,M,CAE,MYL
Zacks
Southern Copper's Tia Maria Construction License Suspended
Southern Copper Corporation's (SCCO) Tia Maria copper mine put on hold following protests owing to environmental concerns.
Simply Wall St.
Don't Sell Boston Scientific Corporation (NYSE:BSX) Before You Read This
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
Zacks
NetApp (NTAP) Q1 Earnings & Revenues Beat Estimates, Down Y/Y
NetApp's (NTAP) fiscal first-quarter revenue decline reflects weakness in storage business, owing to ongoing macro headwinds.
Zacks
What's in the Cards for iQIYI (IQ) This Earnings Season?
iQIYI's (IQ) second-quarter 2019 results are expected to benefit from solid content slate, expanding original content portfolio and partnerships.
Thomson Reuters StreetEvents
Edited Transcript of WTRH earnings conference call or presentation 8-Aug-19 9:00pm GMT
Q2 2019 Waitr Holdings Inc Earnings Call
Thomson Reuters StreetEvents
Edited Transcript of 030200.KS earnings conference call or presentation 7-Aug-19 6:00am GMT
Q2 2019 KT Corp Earnings Call
Thomson Reuters StreetEvents
Edited Transcript of RCII earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Rent-A-Center Inc Earnings Call
Thomson Reuters StreetEvents
Edited Transcript of MUR earnings conference call or presentation 8-Aug-19 2:00pm GMT
Q2 2019 Murphy Oil Corp Earnings Call
Bloomberg
Generic-Drug Giants Accused of Blocking Congressional Probe
(Bloomberg) -- Senator Bernie Sanders and Representative Elijah Cummings are opening an investigation into generic-drug giants Mylan NV and Teva Pharmaceutical Industries Ltd. on allegations of “apparent coordinated obstruction” in failing to provide lawmakers with details about their pricing practices.Sanders, an independent from Vermont who is running for the Democratic nomination for president, and Cummings, a Democrat from Maryland, sent letters to Teva and Mylan as well as closely held Heritage Pharmaceuticals Inc. The letters renewed a 2014 request for the companies to provide documents related to charges of generic-drug price-fixing.The two companies have been at the center of state and federal probes into allegations that generic-drug companies coordinated with one another on setting prices for a range of widely used medications.Lawsuits filed by state attorneys general in 2016 and this year allege a conspiracy among 20 drugmakers to carve up the market and raise prices of more than 100 drugs including commonly prescribed antibiotics as well as medications for reducing cholesterol and controlling seizures. Those actions, authorities allege, cost taxpayers and patients billions of dollars. The prices of some drugs increased by as much as 8,281% between October 2013 and April 2014, according to the lawmakers’ letter made public on Wednesday.The most recent lawsuit included emails from 2014 in which executives at Teva, Mylan and Heritage planned to respond to congressional inquiries with “polite f-u” letters.“Not only did your company’s apparent obstruction undermine our investigation, but it may have caused further harm to patients and health care providers by delaying the discovery of evidence about the companies’ price-fixing,” Sanders and Cummings wrote to the companies on Tuesday. They said withholding or concealing information in a congressional investigation is a violation of federal law.Teva spokeswoman Kelley Dougherty said the company will “continues to cooperate fully with all investigations.”Mylan, which recently announced plans to combine its business with Pfizer Inc.’s unit of older blockbuster medicines, said in a statement that it did not obstruct the 2014 congressional inquiry, and “will continue to cooperate” with investigations.“Mylan respects Congress’s long-standing interest in drug pricing and has worked and will continue to work constructively with Congress to provide it with information relevant to its inquiries,” the company said in a statement.A representative for Pfizer declined to comment. The companies have said they expect their deal to close in mid-2020.A representative for Heritage couldn’t immediately be reached for comment.Mylan fell as much as 8.7% in New York on Wednesday amid a broader stock-market sell-off. Teva’s U.S.-traded stock fell as much as 8.6%; the shares hit their lowest price since 1999 last week when the company set aside $646 million for legal expenses related to its role in the opioid crisis.Probes Hit RoadblocksThe renewed investigation into the drugmakers comes as a federal probe into the generics industry has hit significant obstacles. Over the course of a multiyear Justice Department investigation, only two executives from Heritage Pharmaceuticals have been charged. Both pleaded guilty more than two years ago.The Justice Department will likely bring additional charges soon, Bloomberg reported in July, citing two people familiar with the investigation, though it’s not clear who might be charged. Both people said the probe has encountered challenges, but they said it’s no different from any other complex case. On at least some of the conduct that has come to light, the five-year criminal statute of limitations is set to expire next year.(Updates with comment from Mylan in eighth paragraph.)To contact the reporters on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Zacks
Product Expansion to Aid Applied Materials (AMAT) Q3 Earnings
Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to aid fiscal third-quarter results.
Zacks
Analysts Estimate Pure Storage (PSTG) to Report a Decline in Earnings: What to Look Out for
Pure Storage (PSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Should Value Investors Pick Mylan N.V. (MYL) Stock?
Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.
Zacks
Has Rent-A-Center (RCII) Outpaced Other Consumer Discretionary Stocks This Year?
Is (RCII) Outperforming Other Consumer Discretionary Stocks This Year?
Zacks
Farfetch (FTCH) Catches Eye: Stock Jumps 5.3%
Farfetch (FTCH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Thomson Reuters StreetEvents
Edited Transcript of PLNT earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Planet Fitness Inc Earnings Call
Zacks
Ciena (CIEN) Gains But Lags Market: What You Should Know
Ciena (CIEN) closed at $43.22 in the latest trading session, marking a +0.36% move from the prior day.